The name of the proprietary AIaMD is DERM (Deep Ensemble for the Recognition of Malignancy) and is now in routine use at 19 centers in the United Kingdom. The prospective, post-deployment clinical ...

According to the MHRA’s chief quality and access officer, Dr Laura Squire, there is a need for “risk proportionate regulation of AIaMD […] which takes into account the risks of these ...

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has put out a call for developers of artificial intelligence as a medical device (AIaMD) technology to join its new regulatory ...